Alexion says that its therapy for a rare form of hemolytic anemia, eculizumab, proved successful in a 52-week late stage trial. Researchers said the 97 patients in the study demonstrated a reduced level of fatigue and a reduction in red blood destruction. Alexion says it is also expanding access to the therapy for patients with the disease.
- check out this press release on the data
- here's the AP report